Abstracts tagged "Anti-DNA"

Abstract Number: 1049 • 2016 ACR/ARHP Annual Meeting
High Titer ANA Not Necessarily a Valid Criterion for Lupus – Proposal of a Modification to the Criteria for Classification of SLE
Luis E C Andrade¹, Jan Damoiseaux², Minoru Satoh³, Edward K.L. Chan⁴, Mônica Prado⁵, Henrique Mariz⁶, Renan Agustinelli⁷ and Alessandra Dellavance⁸, ¹Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ²Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Dept of Oral Biology, University of Florida, Gainesville, FL, ⁵Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁶Internal Medicine, Hospital das Clínicas - UFPE, Recife, Brazil, ⁷Rheumatology Division, Escola Paulista de Medicina, São Paulo, Brazil, ⁸Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil
Background/Purpose: A positive ANA test is one of ACR Revised Criteria for Classification of SLE, as well as the SLICC classification. The ANA test provides…
Abstract Number: 781 • 2015 ACR/ARHP Annual Meeting
Anti-Nucleosome Antibodies Versus Anti-DNA Antibodies in the Diagnosis and Monitoring of Activity of Systemic Lupus Erytematosus
Helena Borrell Paños¹, Javier Narváez², Jordi Bas³, Eulàlia Armengol¹, Maria Aparicio¹, Maria Pascual¹, Mercè López de Recalde¹ and Joan Miquel Nolla¹, ¹Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Immunology Department. Hospital Universitari de Bellvitge, Barcelona, Spain
Background/Purpose: Recently, the study of anti-nucleosome antibodies (ANUCs) has been suggested that they may be useful in the diagnosis of systemic lupus erythematosus (SLE) and in…
Abstract Number: 2936 • 2015 ACR/ARHP Annual Meeting
Evolution of Disease Burden over 7 Years in a Multicentre Inception SLE Cohort
Murray Urowitz^1,2, Dafna Gladman¹, Nicole Anderson³, Jiandong Su¹ and Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The evolution on an annual basis of disease activity and damage and the annual accrual of ACR criteria and key autoantibodies in patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].